The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cancer Drug Therapy Market Research Report 2025
Synopsis
Kidney cancer or renal cancer is one of the ten most frequently diagnosed cancers, found mainly in people aged 60 or above. According to the estimates of the American Cancer Society (ACS), 61,560 new kidney cancer cases and 14,080 deaths would occur in 2015. Due to the increasing prevalence with no cure of this deadly disease, till date, there is an imminent need for effective kidney cancer drugs.
The renal cancer drug therapy market has witnessed a dramatic change in its treatment paradigm over the last three decades. Although, there are a variety of treatment options available, innovators have now shifted their focus towards more targeted therapies and immunotherapies. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors boosting the growth of the market. Strong pipeline and fast-emerging treatments are expected to further boost the market during the analysis period. However, high cost of drugs, looming off-patents and uncertain reimbursement policies are some of the factors that are likely to restrain the market growth.
Winning a physicians confidence regarding the cost, efficacy and dosage would lead to a higher acceptance of drugs in the market. Additionally, immunotherapies would emerge as an opportunity for innovators in the kidney cancer drugs market. Furthermore, untapped geographies with a high undiagnosed patient base would offer lucrative opportunities for the innovators in future. However, overcoming the generic drugs competition would be a key challenge for the leading innovators.
The global Cancer Drug Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cancer Drug Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Drug Therapy.
Report Scope
The Cancer Drug Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Drug Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Drug Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen / Allergan
Argos Therapeutics
AstraZeneca
Aveo Pharmaceuticals
Bayer
Exelixis
Incyte
Merck
Roche
Bristol-Myers Squibb
Eisai
Exelixis
Genentech (Roche)
Novartis
Pfizer
Prometheus Labs
Segment by Type
Targeted Therapy
Chemotherapy
Immunotherapy
Segment by Application
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Drug Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Drug Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Kidney cancer or renal cancer is one of the ten most frequently diagnosed cancers, found mainly in people aged 60 or above. According to the estimates of the American Cancer Society (ACS), 61,560 new kidney cancer cases and 14,080 deaths would occur in 2015. Due to the increasing prevalence with no cure of this deadly disease, till date, there is an imminent need for effective kidney cancer drugs.
The renal cancer drug therapy market has witnessed a dramatic change in its treatment paradigm over the last three decades. Although, there are a variety of treatment options available, innovators have now shifted their focus towards more targeted therapies and immunotherapies. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors boosting the growth of the market. Strong pipeline and fast-emerging treatments are expected to further boost the market during the analysis period. However, high cost of drugs, looming off-patents and uncertain reimbursement policies are some of the factors that are likely to restrain the market growth.
Winning a physicians confidence regarding the cost, efficacy and dosage would lead to a higher acceptance of drugs in the market. Additionally, immunotherapies would emerge as an opportunity for innovators in the kidney cancer drugs market. Furthermore, untapped geographies with a high undiagnosed patient base would offer lucrative opportunities for the innovators in future. However, overcoming the generic drugs competition would be a key challenge for the leading innovators.
The global Cancer Drug Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cancer Drug Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Drug Therapy.
Report Scope
The Cancer Drug Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Drug Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Drug Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen / Allergan
Argos Therapeutics
AstraZeneca
Aveo Pharmaceuticals
Bayer
Exelixis
Incyte
Merck
Roche
Bristol-Myers Squibb
Eisai
Exelixis
Genentech (Roche)
Novartis
Pfizer
Prometheus Labs
Segment by Type
Targeted Therapy
Chemotherapy
Immunotherapy
Segment by Application
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Drug Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Drug Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Cancer Drug Therapy Market Overview
1.1 Product Overview and Scope of Cancer Drug Therapy
1.2 Cancer Drug Therapy Segment by Type
1.2.1 Global Cancer Drug Therapy Market Value Comparison by Type (2024-2030)
1.2.2 Targeted Therapy
1.2.3 Chemotherapy
1.2.4 Immunotherapy
1.3 Cancer Drug Therapy Segment by Application
1.3.1 Global Cancer Drug Therapy Market Value by Application: (2024-2030)
1.3.2 Angiogenesis Inhibitors
1.3.3 mTOR Inhibitors
1.3.4 Monoclonal Antibodies
1.3.5 Cytokine Immunotherapy (IL-2)
1.4 Global Cancer Drug Therapy Market Size Estimates and Forecasts
1.4.1 Global Cancer Drug Therapy Revenue 2019-2030
1.4.2 Global Cancer Drug Therapy Sales 2019-2030
1.4.3 Global Cancer Drug Therapy Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Cancer Drug Therapy Market Competition by Manufacturers
2.1 Global Cancer Drug Therapy Sales Market Share by Manufacturers (2019-2024)
2.2 Global Cancer Drug Therapy Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Cancer Drug Therapy Average Price by Manufacturers (2019-2024)
2.4 Global Cancer Drug Therapy Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cancer Drug Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Drug Therapy, Product Type & Application
2.7 Cancer Drug Therapy Market Competitive Situation and Trends
2.7.1 Cancer Drug Therapy Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cancer Drug Therapy Players Market Share by Revenue
2.7.3 Global Cancer Drug Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Drug Therapy Retrospective Market Scenario by Region
3.1 Global Cancer Drug Therapy Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Cancer Drug Therapy Global Cancer Drug Therapy Sales by Region: 2019-2030
3.2.1 Global Cancer Drug Therapy Sales by Region: 2019-2024
3.2.2 Global Cancer Drug Therapy Sales by Region: 2025-2030
3.3 Global Cancer Drug Therapy Global Cancer Drug Therapy Revenue by Region: 2019-2030
3.3.1 Global Cancer Drug Therapy Revenue by Region: 2019-2024
3.3.2 Global Cancer Drug Therapy Revenue by Region: 2025-2030
3.4 North America Cancer Drug Therapy Market Facts & Figures by Country
3.4.1 North America Cancer Drug Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Cancer Drug Therapy Sales by Country (2019-2030)
3.4.3 North America Cancer Drug Therapy Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Cancer Drug Therapy Market Facts & Figures by Country
3.5.1 Europe Cancer Drug Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Cancer Drug Therapy Sales by Country (2019-2030)
3.5.3 Europe Cancer Drug Therapy Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Drug Therapy Market Facts & Figures by Country
3.6.1 Asia Pacific Cancer Drug Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Cancer Drug Therapy Sales by Country (2019-2030)
3.6.3 Asia Pacific Cancer Drug Therapy Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Cancer Drug Therapy Market Facts & Figures by Country
3.7.1 Latin America Cancer Drug Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Cancer Drug Therapy Sales by Country (2019-2030)
3.7.3 Latin America Cancer Drug Therapy Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Drug Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Drug Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Cancer Drug Therapy Sales by Country (2019-2030)
3.8.3 Middle East and Africa Cancer Drug Therapy Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cancer Drug Therapy Sales by Type (2019-2030)
4.1.1 Global Cancer Drug Therapy Sales by Type (2019-2024)
4.1.2 Global Cancer Drug Therapy Sales by Type (2025-2030)
4.1.3 Global Cancer Drug Therapy Sales Market Share by Type (2019-2030)
4.2 Global Cancer Drug Therapy Revenue by Type (2019-2030)
4.2.1 Global Cancer Drug Therapy Revenue by Type (2019-2024)
4.2.2 Global Cancer Drug Therapy Revenue by Type (2025-2030)
4.2.3 Global Cancer Drug Therapy Revenue Market Share by Type (2019-2030)
4.3 Global Cancer Drug Therapy Price by Type (2019-2030)
5 Segment by Application
5.1 Global Cancer Drug Therapy Sales by Application (2019-2030)
5.1.1 Global Cancer Drug Therapy Sales by Application (2019-2024)
5.1.2 Global Cancer Drug Therapy Sales by Application (2025-2030)
5.1.3 Global Cancer Drug Therapy Sales Market Share by Application (2019-2030)
5.2 Global Cancer Drug Therapy Revenue by Application (2019-2030)
5.2.1 Global Cancer Drug Therapy Revenue by Application (2019-2024)
5.2.2 Global Cancer Drug Therapy Revenue by Application (2025-2030)
5.2.3 Global Cancer Drug Therapy Revenue Market Share by Application (2019-2030)
5.3 Global Cancer Drug Therapy Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen / Allergan
6.1.1 Amgen / Allergan Corporation Information
6.1.2 Amgen / Allergan Description and Business Overview
6.1.3 Amgen / Allergan Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen / Allergan Cancer Drug Therapy Product Portfolio
6.1.5 Amgen / Allergan Recent Developments/Updates
6.2 Argos Therapeutics
6.2.1 Argos Therapeutics Corporation Information
6.2.2 Argos Therapeutics Description and Business Overview
6.2.3 Argos Therapeutics Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Argos Therapeutics Cancer Drug Therapy Product Portfolio
6.2.5 Argos Therapeutics Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Corporation Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AstraZeneca Cancer Drug Therapy Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Aveo Pharmaceuticals
6.4.1 Aveo Pharmaceuticals Corporation Information
6.4.2 Aveo Pharmaceuticals Description and Business Overview
6.4.3 Aveo Pharmaceuticals Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Aveo Pharmaceuticals Cancer Drug Therapy Product Portfolio
6.4.5 Aveo Pharmaceuticals Recent Developments/Updates
6.5 Bayer
6.5.1 Bayer Corporation Information
6.5.2 Bayer Description and Business Overview
6.5.3 Bayer Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bayer Cancer Drug Therapy Product Portfolio
6.5.5 Bayer Recent Developments/Updates
6.6 Exelixis
6.6.1 Exelixis Corporation Information
6.6.2 Exelixis Description and Business Overview
6.6.3 Exelixis Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Exelixis Cancer Drug Therapy Product Portfolio
6.6.5 Exelixis Recent Developments/Updates
6.7 Incyte
6.6.1 Incyte Corporation Information
6.6.2 Incyte Description and Business Overview
6.6.3 Incyte Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Incyte Cancer Drug Therapy Product Portfolio
6.7.5 Incyte Recent Developments/Updates
6.8 Merck
6.8.1 Merck Corporation Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Merck Cancer Drug Therapy Product Portfolio
6.8.5 Merck Recent Developments/Updates
6.9 Roche
6.9.1 Roche Corporation Information
6.9.2 Roche Description and Business Overview
6.9.3 Roche Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Roche Cancer Drug Therapy Product Portfolio
6.9.5 Roche Recent Developments/Updates
6.10 Bristol-Myers Squibb
6.10.1 Bristol-Myers Squibb Corporation Information
6.10.2 Bristol-Myers Squibb Description and Business Overview
6.10.3 Bristol-Myers Squibb Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Bristol-Myers Squibb Cancer Drug Therapy Product Portfolio
6.10.5 Bristol-Myers Squibb Recent Developments/Updates
6.11 Eisai
6.11.1 Eisai Corporation Information
6.11.2 Eisai Cancer Drug Therapy Description and Business Overview
6.11.3 Eisai Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Eisai Cancer Drug Therapy Product Portfolio
6.11.5 Eisai Recent Developments/Updates
6.12 Exelixis
6.12.1 Exelixis Corporation Information
6.12.2 Exelixis Cancer Drug Therapy Description and Business Overview
6.12.3 Exelixis Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Exelixis Cancer Drug Therapy Product Portfolio
6.12.5 Exelixis Recent Developments/Updates
6.13 Genentech (Roche)
6.13.1 Genentech (Roche) Corporation Information
6.13.2 Genentech (Roche) Cancer Drug Therapy Description and Business Overview
6.13.3 Genentech (Roche) Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Genentech (Roche) Cancer Drug Therapy Product Portfolio
6.13.5 Genentech (Roche) Recent Developments/Updates
6.14 Novartis
6.14.1 Novartis Corporation Information
6.14.2 Novartis Cancer Drug Therapy Description and Business Overview
6.14.3 Novartis Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Novartis Cancer Drug Therapy Product Portfolio
6.14.5 Novartis Recent Developments/Updates
6.15 Pfizer
6.15.1 Pfizer Corporation Information
6.15.2 Pfizer Cancer Drug Therapy Description and Business Overview
6.15.3 Pfizer Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Pfizer Cancer Drug Therapy Product Portfolio
6.15.5 Pfizer Recent Developments/Updates
6.16 Prometheus Labs
6.16.1 Prometheus Labs Corporation Information
6.16.2 Prometheus Labs Cancer Drug Therapy Description and Business Overview
6.16.3 Prometheus Labs Cancer Drug Therapy Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Prometheus Labs Cancer Drug Therapy Product Portfolio
6.16.5 Prometheus Labs Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Drug Therapy Industry Chain Analysis
7.2 Cancer Drug Therapy Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Drug Therapy Production Mode & Process
7.4 Cancer Drug Therapy Sales and Marketing
7.4.1 Cancer Drug Therapy Sales Channels
7.4.2 Cancer Drug Therapy Distributors
7.5 Cancer Drug Therapy Customers
8 Cancer Drug Therapy Market Dynamics
8.1 Cancer Drug Therapy Industry Trends
8.2 Cancer Drug Therapy Market Drivers
8.3 Cancer Drug Therapy Market Challenges
8.4 Cancer Drug Therapy Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Cancer Drug Therapy Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Cancer Drug Therapy Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Cancer Drug Therapy Market Competitive Situation by Manufacturers in 2023
Table 4. Global Cancer Drug Therapy Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Cancer Drug Therapy Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Cancer Drug Therapy Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Cancer Drug Therapy Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Cancer Drug Therapy Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Cancer Drug Therapy, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Cancer Drug Therapy, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Cancer Drug Therapy, Product Type & Application
Table 12. Global Key Manufacturers of Cancer Drug Therapy, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Cancer Drug Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Drug Therapy as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Cancer Drug Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Cancer Drug Therapy Sales by Region (2019-2024) & (K Units)
Table 18. Global Cancer Drug Therapy Sales Market Share by Region (2019-2024)
Table 19. Global Cancer Drug Therapy Sales by Region (2025-2030) & (K Units)
Table 20. Global Cancer Drug Therapy Sales Market Share by Region (2025-2030)
Table 21. Global Cancer Drug Therapy Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Cancer Drug Therapy Revenue Market Share by Region (2019-2024)
Table 23. Global Cancer Drug Therapy Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Cancer Drug Therapy Revenue Market Share by Region (2025-2030)
Table 25. North America Cancer Drug Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Cancer Drug Therapy Sales by Country (2019-2024) & (K Units)
Table 27. North America Cancer Drug Therapy Sales by Country (2025-2030) & (K Units)
Table 28. North America Cancer Drug Therapy Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Cancer Drug Therapy Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Cancer Drug Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Cancer Drug Therapy Sales by Country (2019-2024) & (K Units)
Table 32. Europe Cancer Drug Therapy Sales by Country (2025-2030) & (K Units)
Table 33. Europe Cancer Drug Therapy Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Cancer Drug Therapy Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Cancer Drug Therapy Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Cancer Drug Therapy Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Cancer Drug Therapy Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Cancer Drug Therapy Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Cancer Drug Therapy Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Cancer Drug Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Cancer Drug Therapy Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Cancer Drug Therapy Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Cancer Drug Therapy Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Cancer Drug Therapy Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Cancer Drug Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Cancer Drug Therapy Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Cancer Drug Therapy Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Cancer Drug Therapy Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Cancer Drug Therapy Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Cancer Drug Therapy Sales (K Units) by Type (2019-2024)
Table 51. Global Cancer Drug Therapy Sales (K Units) by Type (2025-2030)
Table 52. Global Cancer Drug Therapy Sales Market Share by Type (2019-2024)
Table 53. Global Cancer Drug Therapy Sales Market Share by Type (2025-2030)
Table 54. Global Cancer Drug Therapy Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Cancer Drug Therapy Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Cancer Drug Therapy Revenue Market Share by Type (2019-2024)
Table 57. Global Cancer Drug Therapy Revenue Market Share by Type (2025-2030)
Table 58. Global Cancer Drug Therapy Price (USD/Unit) by Type (2019-2024)
Table 59. Global Cancer Drug Therapy Price (USD/Unit) by Type (2025-2030)
Table 60. Global Cancer Drug Therapy Sales (K Units) by Application (2019-2024)
Table 61. Global Cancer Drug Therapy Sales (K Units) by Application (2025-2030)
Table 62. Global Cancer Drug Therapy Sales Market Share by Application (2019-2024)
Table 63. Global Cancer Drug Therapy Sales Market Share by Application (2025-2030)
Table 64. Global Cancer Drug Therapy Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Cancer Drug Therapy Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Cancer Drug Therapy Revenue Market Share by Application (2019-2024)
Table 67. Global Cancer Drug Therapy Revenue Market Share by Application (2025-2030)
Table 68. Global Cancer Drug Therapy Price (USD/Unit) by Application (2019-2024)
Table 69. Global Cancer Drug Therapy Price (USD/Unit) by Application (2025-2030)
Table 70. Amgen / Allergan Corporation Information
Table 71. Amgen / Allergan Description and Business Overview
Table 72. Amgen / Allergan Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Amgen / Allergan Cancer Drug Therapy Product
Table 74. Amgen / Allergan Recent Developments/Updates
Table 75. Argos Therapeutics Corporation Information
Table 76. Argos Therapeutics Description and Business Overview
Table 77. Argos Therapeutics Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Argos Therapeutics Cancer Drug Therapy Product
Table 79. Argos Therapeutics Recent Developments/Updates
Table 80. AstraZeneca Corporation Information
Table 81. AstraZeneca Description and Business Overview
Table 82. AstraZeneca Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. AstraZeneca Cancer Drug Therapy Product
Table 84. AstraZeneca Recent Developments/Updates
Table 85. Aveo Pharmaceuticals Corporation Information
Table 86. Aveo Pharmaceuticals Description and Business Overview
Table 87. Aveo Pharmaceuticals Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Aveo Pharmaceuticals Cancer Drug Therapy Product
Table 89. Aveo Pharmaceuticals Recent Developments/Updates
Table 90. Bayer Corporation Information
Table 91. Bayer Description and Business Overview
Table 92. Bayer Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Bayer Cancer Drug Therapy Product
Table 94. Bayer Recent Developments/Updates
Table 95. Exelixis Corporation Information
Table 96. Exelixis Description and Business Overview
Table 97. Exelixis Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Exelixis Cancer Drug Therapy Product
Table 99. Exelixis Recent Developments/Updates
Table 100. Incyte Corporation Information
Table 101. Incyte Description and Business Overview
Table 102. Incyte Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Incyte Cancer Drug Therapy Product
Table 104. Incyte Recent Developments/Updates
Table 105. Merck Corporation Information
Table 106. Merck Description and Business Overview
Table 107. Merck Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Merck Cancer Drug Therapy Product
Table 109. Merck Recent Developments/Updates
Table 110. Roche Corporation Information
Table 111. Roche Description and Business Overview
Table 112. Roche Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Roche Cancer Drug Therapy Product
Table 114. Roche Recent Developments/Updates
Table 115. Bristol-Myers Squibb Corporation Information
Table 116. Bristol-Myers Squibb Description and Business Overview
Table 117. Bristol-Myers Squibb Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Bristol-Myers Squibb Cancer Drug Therapy Product
Table 119. Bristol-Myers Squibb Recent Developments/Updates
Table 120. Eisai Corporation Information
Table 121. Eisai Description and Business Overview
Table 122. Eisai Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. Eisai Cancer Drug Therapy Product
Table 124. Eisai Recent Developments/Updates
Table 125. Exelixis Corporation Information
Table 126. Exelixis Description and Business Overview
Table 127. Exelixis Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. Exelixis Cancer Drug Therapy Product
Table 129. Exelixis Recent Developments/Updates
Table 130. Genentech (Roche) Corporation Information
Table 131. Genentech (Roche) Description and Business Overview
Table 132. Genentech (Roche) Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 133. Genentech (Roche) Cancer Drug Therapy Product
Table 134. Genentech (Roche) Recent Developments/Updates
Table 135. Novartis Corporation Information
Table 136. Novartis Description and Business Overview
Table 137. Novartis Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 138. Novartis Cancer Drug Therapy Product
Table 139. Novartis Recent Developments/Updates
Table 140. Pfizer Corporation Information
Table 141. Pfizer Description and Business Overview
Table 142. Pfizer Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 143. Pfizer Cancer Drug Therapy Product
Table 144. Pfizer Recent Developments/Updates
Table 145. Prometheus Labs Corporation Information
Table 146. Prometheus Labs Description and Business Overview
Table 147. Prometheus Labs Cancer Drug Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 148. Prometheus Labs Cancer Drug Therapy Product
Table 149. Prometheus Labs Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Cancer Drug Therapy Distributors List
Table 153. Cancer Drug Therapy Customers List
Table 154. Cancer Drug Therapy Market Trends
Table 155. Cancer Drug Therapy Market Drivers
Table 156. Cancer Drug Therapy Market Challenges
Table 157. Cancer Drug Therapy Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cancer Drug Therapy
Figure 2. Global Cancer Drug Therapy Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Cancer Drug Therapy Market Share by Type in 2023 & 2030
Figure 4. Targeted Therapy Product Picture
Figure 5. Chemotherapy Product Picture
Figure 6. Immunotherapy Product Picture
Figure 7. Global Cancer Drug Therapy Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Cancer Drug Therapy Market Share by Application in 2023 & 2030
Figure 9. Angiogenesis Inhibitors
Figure 10. mTOR Inhibitors
Figure 11. Monoclonal Antibodies
Figure 12. Cytokine Immunotherapy (IL-2)
Figure 13. Global Cancer Drug Therapy Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Cancer Drug Therapy Market Size (2019-2030) & (US$ Million)
Figure 15. Global Cancer Drug Therapy Sales (2019-2030) & (K Units)
Figure 16. Global Cancer Drug Therapy Average Price (USD/Unit) & (2019-2030)
Figure 17. Cancer Drug Therapy Report Years Considered
Figure 18. Cancer Drug Therapy Sales Share by Manufacturers in 2023
Figure 19. Global Cancer Drug Therapy Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Cancer Drug Therapy Players: Market Share by Revenue in 2023
Figure 21. Cancer Drug Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Cancer Drug Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Cancer Drug Therapy Sales Market Share by Country (2019-2030)
Figure 24. North America Cancer Drug Therapy Revenue Market Share by Country (2019-2030)
Figure 25. U.S. Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Cancer Drug Therapy Sales Market Share by Country (2019-2030)
Figure 28. Europe Cancer Drug Therapy Revenue Market Share by Country (2019-2030)
Figure 29. Germany Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Cancer Drug Therapy Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Cancer Drug Therapy Revenue Market Share by Region (2019-2030)
Figure 36. China Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Taiwan Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Philippines Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Latin America Cancer Drug Therapy Sales Market Share by Country (2019-2030)
Figure 47. Latin America Cancer Drug Therapy Revenue Market Share by Country (2019-2030)
Figure 48. Mexico Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Cancer Drug Therapy Sales Market Share by Country (2019-2030)
Figure 52. Middle East & Africa Cancer Drug Therapy Revenue Market Share by Country (2019-2030)
Figure 53. Turkey Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. UAE Cancer Drug Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Global Sales Market Share of Cancer Drug Therapy by Type (2019-2030)
Figure 57. Global Revenue Market Share of Cancer Drug Therapy by Type (2019-2030)
Figure 58. Global Cancer Drug Therapy Price (USD/Unit) by Type (2019-2030)
Figure 59. Global Sales Market Share of Cancer Drug Therapy by Application (2019-2030)
Figure 60. Global Revenue Market Share of Cancer Drug Therapy by Application (2019-2030)
Figure 61. Global Cancer Drug Therapy Price (USD/Unit) by Application (2019-2030)
Figure 62. Cancer Drug Therapy Value Chain
Figure 63. Cancer Drug Therapy Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
